Previous 10 | Next 10 |
ISS Acknowledges Ziopharm’s Outperformance of its Peer Group During Chairman Scott Tarriff’s Tenure Court Filings R aise Concerns About Professional Past of WaterMill Nominee Holger Weis Ziopharm Recommends Sh...
A Leading Proxy Advisory Firm Supports the Addition of WaterMill Nominees Jaime Vieser and Holger Weis Recommends for the Removal of Chairman Scott Tarriff and Director Elan Ezickson Report Notes That “Additional Representation of Shareowners on the Bo...
Issues New Rebuttal Presentation that Systematically Exposes and Refutes the Distortions in Ziopharm’s November 19 th Deck Makes Clear That Shareholders Have Been Continuously Harmed by Value-Destructive Business Decisions Before and After Ziopharm’s Di...
The following slide deck was published by ZIOPHARM Oncology, Inc. in conjunction with this event. For further details see: Ziopharm Oncology (ZIOP) Investor Presentation - Slideshow
Ziopharm Oncology ([[ZIOP]] +4.2%) today released an investor presentation highlighting its successful developments, as well as says 75% of its current directors joined after separation from Intrexon, and have relevant experience and expertise.The company says that WaterMill’s attacks ...
Co ntinues to Execute on Strategy to Ensure Strong Long-Term Outlook Outlines Additions of Five Highly Qualified Industry Veteran s to Board Over the Last 18 Months BOSTON, Nov. 20, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc....
Highlights the Incumbent Board’s Anti-Shareholder Practices, Concerning Interconnectivity, and Record of Presiding Over Negative Returns Across Every Relevant Time Horizon Makes Clear That Ziopharm is on a Path to Financial Ruin as its Capital Position Shrinks, G&...
White Rock Capital Supports WaterMill's Case for Change at Ziopharm Oncology PR Newswire DALLAS, Nov. 19, 2020 DALLAS , Nov. 19, 2020 /PRNewswire/ -- White Rock Capital Partners, L.P. ("White Rock Capital"), along with all of its related entities, will v...
– First Data from Ongoing Phase 2 Study of Controlled IL-12 in Combination with Cemiplimab Demonstrate Promising Safety Profile in rGBM, and a Confirmed Partial Response – – Updated Interim Data from Ongoing Phase 1 Study of Controlled IL-12 in Combination...
– Pharmaceutical Executive with 2 0 + Year s of Experience Across All Phases of Clinical Research Including IND Submission s , Trial Design and Regulatory Filings – – Former Chief Medical Officer for ...
News, Short Squeeze, Breakout and More Instantly...
ZIOPHARM Oncology Inc Company Name:
ZIOP Stock Symbol:
NASDAQ Market:
ZIOPHARM Oncology Inc Website:
TCR-T Library Phase 1/2 trial achieved an 87% disease control rate of eight evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all treated patients hunTR® discovered new HLA class I and class II restricted TCRs that recognize d...
TCR-T Library Phase 1/2 trial achieved an 83% disease control rate of six evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all evaluable patients Company to wind down TCR-T Library Phase 1/2 trial and concurrently explore potent...
HOUSTON, June 29, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that the Compan...